Participated · Seed · Apr 2026

Acurion develops the OncoGaze™ platform, an AI-powered image analysis system that detects clinically actionable cancer biomarkers from routine pathology slides. The technology is positioned to extract biomarker insights without requiring additional tissue or specialized molecular testing. Acurion builds on foundational research from co-founder and CSO Ludmil Alexandrov, Ph.D., and has published in leading oncology and scientific journals while expanding clinical collaborations. The company says it is moving from validation toward deployment and is focusing on clinical and regulatory milestones. Acurion closed an oversubscribed $4.3 million seed round to fund clinical validation, platform development, regulatory preparation, and commercialization. The company expects to announce further clinical collaborations and regulatory progress in the coming months.

Led · Equity · Jun 2023

SciTech Development is a clinical-stage pharmaceutical company focused on advancing next-generation cancer therapeutics via its proprietary nanotechnology drug-delivery platform. Its lead candidate, ST-001 nanoFenretinide, is in clinical trials for T-cell Non-Hodgkin Lymphoma across nine cancer centers and has produced a 100% disease control rate at the highest tested dose levels, including confirmed partial responses. Interim data suggest efficacy in both early- and late-stage patients, minimal side effects, and confirmed safety, encouraging participants to remain in the study. The company intends to extend clinical development of ST-001 into Small Cell Lung Cancer and explore additional oncology indications. Investor enthusiasm has been fueled by these results, enabling continued trial progress and pipeline expansion. SciTech has not reported commercial revenue, relying instead on successive convertible note financings to fund operations.

Led · Series A · May 2021

TellBio, founded in 2019 and based in Beverly, Massachusetts, develops a proprietary circulating tumor cell (CTC) technology (TellDx) and a complementary therapeutics platform (TellRx). TellDx is a microfluidic diagnostic solution designed to detect live CTCs from patient liquid biopsies and is described as revenue-generating. TellRx is an early-stage therapeutics platform focused on generating anti-cancer medicines that specifically target CTCs. The company’s CTC approach and technology are exclusively licensed from Massachusetts General Hospital and originate from decades of academic and clinical research by its scientific founders. TellBio plans to use recent financing to further deploy TellDx globally and to advance TellRx programs in early-stage development. Strategic agreements announced concurrently — an exclusive TellDx license to Genetron for greater China and deployment at ARUP Laboratories in the U.S. — are intended to accelerate global commercialization and research adoption.